THE WELCH COMPANY
440 Davis Court #1602
San Francisco, CA 94111-2496
415 781 5700
rodwelch@pacbell.net


S U M M A R Y


DIARY: April 19, 2007 08:30 AM Thursday; Rod Welch

Millie meeting at UCSF 3rd cycle 4th treatment cetuximab for IBC.

1...Summary/Objective
2...Agenda Develop Work Plan Stage IV Breast Cancer 15 Mos after Mastectomy
3...Complex Patient History Knowledge Management Dilemma Issues Grow 45
4...Vitals Show Stable Medical Condition
5...Coordination Plan Divided Responsibilities Kaiser UCSF Referral
6...Collaboration Primary Care at Kaiser with UCSF Clinical Study Cetuximab
7...CA 15-3 Cancer Marker 33 Showing Significant Improvement
8...CA 15-3 33 Cancer Marker Strong Response to Treatment Cetuximab
9...Axillary Left Arm No Lymphadenopathy Lymphedema Prominent
10...Lymphadenopathy Axillary Left Arm No Evidence Local Edema
11...Lymphedema Cellulitis Complications Left Arm Swelling
12...Swelling Left Arm Lymphedema Cellulitis Complications
13...Left Arm Lymphedema Cellulitis Complications Swelling Above Normal
14...Cellulitis Lymphedema Complications Left Arm Swelling Above Normal
15...Redness Swelling Inflammation Side Effects Cetuximab
16...Intelligence Support Computer Examination Room UCSF Internet Research
17...Computer Examination Room Intelligence Support UCSF Internet Research
18...UCSF Internet Research Computer Examination Room Intelligence Support
19...Cat Bite Erratic Inflammation Fever Low Blood Counts
20...IBC Left Arm Stable Subsiding Responds Treatment Cetuximab Drug Trial
21...Left Arm IBC Stable Subsiding Responds Treatment Cetuximab Drug Trial
22...Right Axillary Possible Involvement Red Rash Spreads Right Breast
23...IBC Right Arm New Minimal Red Rash Not Diagnosed IBC or Cellulitis
24...Right Breast Red Rash Spreads Possible Involvement Right Axillary
25...Red Rash Right Breast Spreads Possible Involvement Right Axillary
26...Right Chest Rash Not Visible Above Breast and Port Catheter
27...Rash Above Port Catheter on Right Upper Chest Not Visible Today
28...Port Catheter Infection Blemish Right Chest Blood Culture Investigate
29...Left Supraclavicular Examination PET Test Report Finding SUV 4.5
30...Prognosis Stage IV Metastatic Disease Relapse IBC Seems Likely
31...Lumps in Neck Reported 040309 Establish Stage IV Metastatic Cancer
32...2 Scenarios Conflict IBC Expanding Intensity Subsides
33...IBC Rash Left Breast Stomach and Back Seems to Be Subsiding
34...Examination IBC Rash Subsiding Responding to Treatment Cetuximab
35...Cetuximab Effective Treatment IBC Subsiding Left Breast Stomach Back
36...Prognosis Very Good IBC Stable Cetuximab Clinical Study
37...Stable Low Intensity IBC Rash Very Good Response to Treatment
38...Cetuximab Prognosis Good Chance IBC Rash 3rd Relapse Will Clear Up Again
39...Distant Metastasis No Evidence Patient History Examinations Tests
40...Local IBC Infection No Record Distant Metastasis Improves Chances
41...Prognosis Favorable No Lymphadenopathy 2006 No Distant Metastasis 5 Years
42...Wicked Problem Resolved Disease Subsides ANC Rises to Safe Level
43...ANC 1.87 Blood Counts Rise Above Safe Level for Treatment with Cetuximab
44...Measurable Disease IBC No New Sites No Expansion Intensity Declines
45...Photographs Record Measurable Disease IBC Tumor in Dermal Tissue
46...Measurable Disease IBC Observed with Tape Measure Photograph Pictures
47...CA 15-3 Diagnostic Measurable Disease IBC Not Measured by Image Testing
48...Lung Cancer Lymph Nodes Doctor's Progress Notes Medical Chart
49...Metastatic Cancer Lung Lymph Node Progress Notes Medical Chart
50...Biopsy Erratic Changes Rash Intensity Verify IBC Left Arm
51...Emotional Trauma Rising Falling Cancer Symptoms Risks Image Testing
52...Exercise Vigor Strength Engagement Ease Distress Living with Cancer
53...Behavior Medical Specialist (BMS) Emotional Counseling Not Effective
54...Sleeping Difficulty Subsides Health Issues Medical Management Improve
55...Planning Case Management from Patient Profile Work Up
56...Work Up Patient Profile Develop Options Strategy Treatment IBC Relapse
57...Strategy Cetuximab Continued with Low ANC Expanding IBC Disease
58...Treatment 3rd Cycle Cetuximab Carboplatin 070329 10th Cycle 3rd Relapse
59...10th Cycle Treatment IBC 3rd Relapse 3rd Cycle Cetuximab Clinical Study
60...Cetuximab 3rd Cycle 1st Treatment IBC 3rd Relapse Clinical Study Drug Trial
61...Side Effects Cetuximab Similar Symptoms Pulmonary Embolism
62...Energy Strength Rising Minimal Side Effects Cetuximab Treatment
63...Facial Skin Dryness New Side Effect Cetuximab Curel Lotion Prescribed
64...Curel Lotion Prescribed Facial Skin Dryness New Side Effect Cetuximab
65...Cetuximab UCSF Clinical Study Treatment Begins 070201
66...UCSF Clinical Study Treatment Cetuximab Drug Trial Begins 070201
67...Drug Trials UCSF Has Other Clinical Study Treatments May Help Millie
68...Schedule Treatment Start Cetuximab Carboplatin 070201
69...Tired Breathing Difficulty Routine Activity Signals Pulmonary Emboli
70...Coumadin Treatment Pulmonary Emboli Family History Genetic Cause
71...Pulmonary Emboli Hypercoagulable Work Up PET Scan Test Compare History
72...INR 2.4 Blood Test Patient Stable for Coumadin Treatments Pulmonary Emboli
73...Examination Breathing Stethoscope No Finding Enlarged Right Ventricle
74...Cor Pulmonale Heart Disorder Enlarged Right Ventricle
75...Heart Examination Not Ordered Investigate Enlarged Right Ventricle
76...Enlarged Right Ventricle CT Test Aligns Patient Symptoms How Serious

ACTION ITEMS.................. Click here to comment!

1...Consideration might be given to notifying the surgeon, who installed

CONTACTS 

SUBJECTS
Meeting Examination Doctor 15th Review Start Treatment #19 After Mas

1403 -
1403 -    ..
1404 - Summary/Objective
1405 -
140501 - Follow up ref SDS D6 0000. ref SDS D3 0000.
140502 -
140503 - Clinical examination today was out of sequence on the 4th treatment in
140504 - the cycle. ref SDS 0 SM6M  Shows subsiding and stable IBC rash, with
140505 - no new sites since treatment started 070201 on the cetuximab clinical
140506 - study. ref SDS 0 LB5L  Recent redness and inflammation on the upper
140507 - left arm, and on the right chest below the collar bone may be side
140508 - effects of cetuximab, and not progression of IBC disease. ref SDS 0
140509 - 116J   Doctor Rugo noticed a large blemish above the port catheter on
140510 - the right chest.  She ordered a culture with a blood test. ref SDS 0
140511 - S640  This could be an infection caused by cetuximab. ref SDS 0 EZ8K
140512 - Cat bites have previously caused fever, inflammation and swelling of
140513 - skin, and Millie recently suffered this problem again. ref SDS 0 P67J
140514 - Results of blood tests were negative on the culture, and showed blood
140515 - counts NEUTS 1.87 (ANC 1870), continuing to strengthen the immune
140516 - system that helps resist cancer. ref SDS 0 VF5M
140517 -
140518 -
140519 -
140521 -  ..
1406 -
1407 -
1408 - Progress
1409 -
140901 - Agenda Develop Work Plan Stage IV Breast Cancer 15 Mos after Mastectomy
140902 -
140903 - Follow up ref SDS D6 SM6M, ref SDS D3 SM6M.
140904 -
140905 - The meeting today was scheduled last week on 070412 to occur out of
140906 - sequence for the treatment protocol. ref SDS D8 FO6H
140908 -  ..
140909 - This is the 15th physician meeting to treat the 3rd relapse of IBC
140910 - shown on 060711. ref SDS 82 8Y8I  Normally meetings with Doctor Rugo
140911 - occur starting a new cycle, which will be next week.  The doctor will
140912 - not be available next week, and so meets with Millie today, as planned
140913 - on 070412. ref SDS D8 FO6H  Examination today evaluates patient status
140914 - starting the 19th treatment during the 10th chemotherapy cycle since
140915 - treatments began on 060721 for recurrent disease after mastectomy
140916 - surgery on 051021. ref SDS 72 E74F  This is the 4th meeting scheduled
140917 - with Doctor Rugo, and occurs during the 3rd cycle and 12th treatment
140918 - with cetuximab, ref SDS E0 PR8Q, on a clinical study drug trial
140919 - ordered by the primary care physician on 070105. ref SDS A5 PK68
140921 -  ..
140922 - Complete list of treatments for IBC 3rd relapse is reported in the
140923 - record of treatment following the meeting today. ref SDS E0 7T3H
140925 -  ..
140926 - Agenda for meeting at UCSF on 070329 provides a structure for planning
140927 - the meeting today...
140928 -
140929 -    1.  Coordination plan.............................. ref SDS 0 RM4G
140930 -    2.  CA 15-3 33 improvement......................... ref SDS 0 GJ5M
140931 -    3.  Lymphedema restricts exercise.................. ref SDS 0 4Y93
140932 -    4.  Breast exam IBC stable subsides................ ref SDS 0 025H
140933 -    5.  Measurable disease declines.................... ref SDS 0 M652
140934 -    6.  Side effects minimal........................... ref SDS 0 TQ6L
140935 -    7.  CT no distant metastasis, no test for PE....... ref SDS 0 EY5O
140936 -    8.  Patient work up continue strategy.............. ref SDS 0 K36G
140937 -    9.  Treatment plan weekly clinical trial........... ref SDS 0 PF3O
140938 -   10.  Pulmonary emboli how serious r ventricle....... ref SDS 0 CV5L
140940 -  ..
140941 - Scheduled next meeting for Thursday 070426 0800, reported in the
140942 - record on 070315. ref SDS C6 159O
140944 -  ..
140945 - The doctor was assisted by (2) aides...
140946 -
140947 -        1.  Brigid, Nurse Practitioner
140948 -        2.  Jackie, Clinical Research Coordinator, coordinating
140949 -
140950 -
140951 -
140952 -
1410 -

SUBJECTS
Complex Patient History 44 Issues Overwhelms Span of Attention Drive

2203 -
220401 -  ..
220402 - Complex Patient History Knowledge Management Dilemma Issues Grow 45
220403 -
220404 - Follow up ref SDS D6 LU3J, ref SDS D3 LU3J.
220405 -
220406 - Sampling of issues patient history diagnosis and treatment...
220407 -
220408 -    1.  CA 15-3 monitors advance of cancer response to treatment
220409 -    2.  Lymphedema complicated by mastectomy surgery
220410 -    3.  Broken finger from minor fall complicates lymphedema
220411 -    4.  Esophagitis reflux digestion issues
220412 -    5.  Immune system chemotherapy increases risk of infection
220413 -        Chemotherapy increase risk of infection
220414 -    6.  Cat bites increase risk of infection complicates lymphedema
220415 -    7.  Pneumonia chemotherapy increases risk of infection
220416 -    8.  Metastatic cancer increases risk pulmonary embolism
220417 -    9.  Lymphadenopathy left axilla local regional metastasis
220418 -   10.  Lymphadenopathy right axilla distant metastasis
220419 -   11.  Lymphadenopathy left supraclavicular diagnose metastatic cancer
220420 -   12.  Breast cancer secondary IBC 3rd relapse left breast
220421 -   13.  Cancer mutates slow response chemotherapy treatment
220422 -   14.  Mastectomy surgery impact on treatment IBC relapse
220423 -   15.  Blood vessels removed mastectomy slow chemotherapy treatments
220424 -   16.  Treatment options, strategy, planning, schedule
220425 -   17.  Drug trials increase declining pool chemotherapy agents
220426 -   18.  UCSF Doctor Benz 2nd opinion apply diagnosis and treatment
220427 -   19.  Pulmonary embolism blood clots in lungs
220428 -   20.  INR weekly adjustments Coumadin treatment blood clots
220429 -   21.  Enlarged right ventricle heart problem core pulmonale
220430 -   22.  Dizziness symptom enlarged right ventricle cor pulmonale
220431 -   23.  Fatigue shortness breath side effect chemotherapy loss fitness
220432 -   24.  Fatigue shortness breath symptom pulmonary embolism
220433 -   25.  Shortness breath fatigue dizzy symptoms pulmonary embolism
220434 -   26.  Coagulapathy hypercoagulable state work up genetic risks
220435 -   27.  Testing resolution of errors (see Benz 2nd opinion 060821)
220436 -   28.  Testing distant metastatic disease
220437 -   29.  Testing pulmonary embolism and heart disease
220438 -   30.  Communication hectic schedule not enough time to manage details
220439 -   31.  Emotional stress and well being
220440 -   32.  Cellulitis inflammation temperature 102.6 on chemotherapy
220441 -   33.  Urinary tract bladder infection
220442 -   34.  IBC rash spreads to right breast
220443 -   35.  Right breast rash may be "ring" infection, not cancer
220444 -   36.  Lung cancer seems to be diagnosed in the Medical Chart
220445 -   37.  IBC rash spreads to stomach and toward back
220446 -   38.  IBC rash spreads to left arm
220447 -   39.  Dry skin face chest arm
220448 -   40.  Right arm evidence light red rash, may be IBC spreading
220449 -   41.  Rash right upper right chest near port catheter
220450 -   42.  Restless legs side effect Benadryl pre-treatment
220451 -   43.  Sleeping difficulty side effect cetuximab
220452 -   44.  Rash intense .5" round rash about .75" above port catheter
220453 -   45.  Sleep nap after cetuximab treatment fatigue accumulating
220454 -
220455 -
220456 -
220457 -
2205 -

SUBJECTS
Vitals Submitted by Doctor UCSF Blood Pressure Pulse Normal Low Anxi

2803 -
280401 -  ..
280402 - Vitals Show Stable Medical Condition
280403 -
280404 - Follow up ref SDS D6 KB5L, ref SDS D3 KB5L.
280406 -                           ..
280407 -                          Bld Prssr   Pulse   Temp   Weight  SaO2
280408 -     ..
280409 -    070419 1230............ 133  79    57     36.3c            98
280410 -    070419 1130............ 141  78    56     37.6c **1        99
280411 -    070419 0930............ 153  80    53     36.1c   147     100
280412 -    070330 1540............ 136 92     52     99.4    150      98
280413 - *  070329 0900............ 141 76     60     36.6c            99
280414 - *  070301 1505............ 112 69     86     36.6c            98
280415 - *  070130 1300............ 140 83     87     98
280416 -    070105 1040............
280417 -    061208 1226............ 152 90     76     97.8    147     99%
280418 -    061201 1430............ 123 76     76     97.5
280419 -    061110................. 136 83     73     97.0    150     98%
280420 -    061020 1534............ 140 79     67     99.8    151     97
280421 -    060929 1452............ 141 78     66     98.3
280422 -    060908 1335............ 139 79     73     98.1
280423 -    060814 1610............ 139 80     59     98.2
280424 - *  060808.................
280425 -    060711................. 172 87     54     97.5    147
280426 -    060623................. 141 87     71     98.0    147     99%
280427 -    060428................. 129 73     80     99.4    149     99%
280428 -    060217................. 153 81     61     98.6    150     99%
280429 -
280430 - *  For some reason, vitals not submitted, use data from Infusion
280431 -    Clinic during treatment.
280433 -  ..
280434 - High blood pressure reflects pressure on patient about effectiveness
280435 - of new treatment and arrangements between UCSF and Kaiser for timely
280436 - care, discussed on 070130, ref SDS B0 Y642, and again on 070301.
280437 - ref SDS B8 Y642
280439 -  ..
280440 - Today, Millie's vitals are normal, indicating reduced emotional strain
280441 - at this time, as discussed with Brigid on 070315, ref SDS C6 6A7J, and
280442 - reviewed again during the meeting today, per below, ref SDS 0 Y642,
280443 - reflecting changes in patient status reported on 070329. ref SDS D3
280444 - Y642
280445 -
280446 -
280447 -
280448 -
2805 -

SUBJECTS
Coordination Plan Communication UCSF Kaiser Collaboration Improve Di

6803 -
680401 -  ..
680402 - Coordination Plan Divided Responsibilities Kaiser UCSF Referral
680403 - Collaboration Primary Care at Kaiser with UCSF Clinical Study Cetuximab
680404 -
680405 - Follow up ref SDS D6 RM4G, ref SDS D3 RM4G.
680406 -
680407 - Background on coordination plan to manage divided responsibilities
680408 - between Kaiser and referral to UCSF is reported on 070301. ref SDS B8
680409 - RM4G  Case study on 070130 shows requirements for communication to
680410 - strengthen care. ref SDS B0 4T5N  Coordination requirements are listed
680411 - on 070222. ref SDS B6 KL5G
680413 -  ..
680414 - Coordination improved on 070406, when Brigid submitted CA 15-3 results
680415 - via email, ref SDS D7 EQ6I, for the blood test at UCSF on 070329.
680416 - ref SDS D4 2N5J
680418 -  ..
680419 - On 070418, Millie reported appreciation to UCSF for improved
680420 - coordination. ref SDS D9 EQ6I
680422 -  ..
680423 - At that time, on 070418 efforts to coordinate efficiently by sending
680424 - information quickly and accurately using email with links for
680425 - precision access that enables comprehensive review was tried again.
680426 - Millie submitted notice of new rash issues, ref SDS D9 PZ3P, observed
680427 - by the primary care physician during examination at Kaiser on 070330.
680428 - ref SDS D6 474O
680430 -  ..
680431 - This morning Brigid was aware of new rash issues, and that Kaiser had
680432 - prescribed Keflex, but the rash subsided within a few hours, and so
680433 - medication was not taken, pending review by UCSF today, as set out in
680434 - Millie's letter on 070418. ref SDS D9 PZ3P  This shows progress toward
680435 - strengthening coordination using email with precision access to
680436 - patient history.  This aligns with using the computer in the
680437 - examination room for research on the Internet to verify cetuximab side
680438 - effects, discussed below. ref SDS 0 D39M
680440 -  ..
680441 - Brigid also seemed to report during the meeting today being confused
680442 - following some of the links.  This illustrates concerns Jackie cited
680443 - on 070329 that people may need orientation and initial assistance
680444 - using links for precision access. ref SDS D3 L55G  On 000327, Doug
680445 - Engelbart reported similar experience.  Introducing new systems at SRI
680446 - required persistant exposure and support. ref SDS 6 1530  Stuart
680447 - Harrow's work at DCMA on 020905 illustrates benefits of support
680448 - helping people transform to a new way of "working intelligently,"
680449 - ref SDS 15 DAPW, as defined in POIMS. ref OF 1 1X6G
680451 -  ..
680452 - Feedback is a critical aspect of transformation, explained in POIMS,
680453 - ref OF 4 6M4K, and showing possible progress on strengthening
680454 - coordination at this time.
680456 -  ..
680457 - Also, on 070418 Millie provided a link to side effects, ref SDS D9
680458 - PZ4W, listed in the record on 070329. ref SDS D4 QU8K  There wasn't
680459 - enough time this morning for the medical team to access the list using
680460 - the computer in the examination room for comprehensive review of side
680461 - effects.
680462 -
680463 -
680464 -
6805 -

SUBJECTS
CA 15-3 33 Trend Falls Cetuximab Clinical Study Drug Trial Cancer Ma

7503 -
750401 -  ..
750402 - CA 15-3 Cancer Marker 33 Showing Significant Improvement
750403 -
750404 - Follow up ref SDS D6 087J, ref SDS D3 087J.
750405 -
750406 - There was no blood draw today, because the meeting today is out of
750407 - sequence, reported above, ref SDS 0 SM6M, and citing work on 070412.
750408 - ref SDS D8 FO6H   CA 15-3 will be tested next week on 070426, which is
750409 - the normal schedule starting a new cycle.  The most recent test for
750410 - the breast cancer biomarker was on 070329, and results of CA 15-3 33
750411 - were received in a letter from UCSF a week later on 070406.
750412 - ref SDS D7 EQ6I
750414 -           ..
750415 -         Test Date                         Date Received
750416 -          070329......... 33 H............. 070406, ref SDS D7 EQ6I
750417 -          070301......... 36 H............. 070307, ref SDS B9 A16M
750418 -          070215......... 52 H............. 070307, ref SDS B4 ER5O
750419 -          070208......... 55 H............. 070307, ref SDS B4 ER5O
750420 -          070201.....cetuximab begins...... 070201, ref SDS B2 G68I
750421 -          070131......... 56 H............. 070202, ref SDS B3 087J
750422 -          070123......... 52 H............. 070202, ref SDS B3 087J
750423 -          070118......... 68 H............. 070123, ref SDS A9 GK5B
750424 -          070104......... 56 H............. 070110, ref SDS A6 087J
750425 -          061218......... 74 H............. 061227, ref SDS A0 6P9F
750426 -          061214......... 63 H............. 061227, ref SDS A0 6P9F
750427 -          061201....Pause treatments..... . 061201, ref SDS 96 GJ5M
750428 -          061130......... 67 H............. 061201, ref SDS 96 087J
750429 -          061116......... 66 H............. 061201, ref SDS 96 087J
750430 -          061110......... 56 H............. 061201, ref SDS 96 087J
750431 -          061109......... 61 H............. 061110, ref SDS 95 087J
750432 -          061026......... 57 H............. 061110, ref SDS 95 087J
750433 -          061019......... 56 H............. 061020, ref SDS 93 087J
750434 -          060928......... 51 H............. 060929, ref SDS 90 087J
750435 -          060907......... 68 H............. 060929, ref SDS 90 087J
750436 -          060813......... 73 H............. 060817, ref SDS 87 U24M
750437 -          060809......... 87 H............. 060810, ref SDS 86 2N5J
750438 -          060721..Taxotere capecitabine.... 060721, ref SDS 83 0001
750439 -          060708......... 71 H............. 060711, ref SDS 82 087J
750440 -          060616......... 63 H............. 060623, ref SDS 81 UQ5Q
750441 -          060522......... 59 H............. 060605, ref SDS 80 UQ5Q
750442 -          060501......... 49 H............. 060522, ref SDS 79 MC4F
750443 -          060421......... 44 H............. 060428, ref SDS 77 087J
750444 -          060330......... 40 H............. 060428, ref SDS 77 087J
750445 -          060303......... 36............... 060428, ref SDS 77 087J
750446 -          060210......... 33............... 060217, ref SDS 76 087J
750447 -          060109......... 34............... 060126, ref SDS 75 KV59
750448 -          051223......... 34............... 060106, ref SDS 74 087J
750449 -          051202......... 28............... 060106, ref SDS 74 087J
750450 -          051116......... 31............... 051121, ref SDS 73 087J
750451 -          051109......... 30............... 051121, ref SDS 73 087J
750452 -          051102......... 34............... 051121, ref SDS 73 087J
750453 -          051021..Mastectomy surgery....... 051021, ref SDS 72 0001
750454 -          050916...end treatment........... 050916, ref SDS 70 407N
750455 -          050909......... 45 H............. 051007, ref SDS 71 087J
750456 -          050826......... 45 H............. 050913, ref SDS 69 087J
750457 -          050819......... 45 H............. 050913, ref SDS 69 087J
750458 -          050812......... 39 .............. 050819, ref SDS 68 3K6L
750459 -          050729......... 45 H............. 050819, ref SDS 68 EA5G
750460 -          050708......... 46 H............. 050729, ref SDS 67 087J
750461 -          050701......... 37 .............. 050729, ref SDS 67 087J
750462 -          050617......... 45 H............. 050729, ref SDS 67 087J
750463 -          050527......... 56 H............. 050610, ref SDS 65 087J
750464 -          050512......... 67 H............. 050520, ref SDS 63 087J
750465 -          050506......... 80 H............. 050520, ref SDS 63 087J
750466 -  ..
750467 -          050415.........105 H............. 050422, ref SDS 62 087J
750468 -          050415..Taxoter capecitabie begin 050415, ref SDS 61 407N
750469 -          050325.........100 H............. 050329, ref SDS 60 087J
750470 -          050318.........101 H............. 050325, ref SDS 59 2N5J
750471 -          050304......... 88 H............. 050311, ref SDS 57 087J
750472 -          050225......... 95 H............. 050308, ref SDS 56 0001
750473 -          050211......... 78 H............. 050214, ref SDS 55 02BB
750474 -          050128......... 67 H............. 050204, ref SDS 53 087J
750475 -          050104...AC start treatment...... 050104, ref SDS 52 407N
750476 -          041228......... 56 H............. 041230, ref SDS 51 087J
750477 -          041204......... 43 H............. 041210, ref SDS 50 087J
750478 -          041021...Taxol bevczmb ends...... 041021, ref SDS 47 0001
750479 -          041007......... 39............... 041104, ref SDS 48 087J
750480 -          040923......... 49 H............. 041005, ref SDS 46 087J
750481 -          040908......... 44 H............. 040909, ref SDS 45 087J
750482 -          040825......... 47 H............. 040909, ref SDS 45 087J
750483 -          040811......... 42 H............. 040812, ref SDS 44 087J
750484 -          040728......... 43 H............. 040729, ref SDS 42 2N5J
750485 -          040712......... 47 H............. 040713, ref SDS 41 087J
750486 -          040614......... 55 H............. 040615, ref SDS 40 PX6X
750487 -          040517......... 78 H............. 040601, ref SDS 38 2N5J
750488 -          040420...Taxol bevczmb starts.... 040420, ref SDS 36 9Z5J
750489 -          040311......... 70 H............. 040318, ref SDS 31 SM6M
750490 -          040205......... 60 H............. 040211, ref SDS 28 SM6M
750491 -          031201......... 62 H............. 031205, ref SDS 27 SM6M
750492 -          030912......... 66 H............. 030915, ref SDS 26 SM6M
750493 -          030708......... 68 H............. 030710, ref SDS 25 SM6M
750494 -          030503......... 54 H............. 030508, ref SDS 23 SM6M
750495 -          030403......... 45 H............. 030508, ref SDS 23 SM6M
750496 -          030215......... 46 H............. 030220, ref SDS 22 5E6L
750497 -          030106......... 37 H............. 030109, ref SDS 21 SM6M
750498 -          021204..Adjuvant chemo ends...... 021204, ref SDS 20 SQ5I
750499 -          021202......... 41 H?............ 021204, ref SDS 20 SP5G
750500 -          021111......... 36 H?............ 021113, ref SDS 19 Y65I
750501 -          021023......... 33 H?............ 021023, ref SDS 18 SQ5I
750502 -          020930......... 33 H?..39........ 021002, ref SDS 17 SQ5I
750503 -          020917......... 36 H?............ 020924, ref SDS 16 SQ5I
750504 -          020717......... 59 H?............ 020726, ref SDS 14 YN5K
750505 -          020629......... 75 H ............ 020705, ref SDS 13 UX6I
750506 -          020608........  67 H ............ 020614, ref SDS 12 0001
750507 -          020603........ 108 H ............ 020607, ref SDS 11 X67F
750508 -          020511........ 117 H ............ 020603, ref SDS 10 PJ4J
750509 -          020419......... 81 H ............ 020430, ref SDS 9 7N5H
750510 -          020321......... 85 H ............ 020405, ref SDS 8 6T8K
750511 -
750512 -
750513 -
750514 -
750516 -  ..
7506 -
7507 -
7508 - Analysis
7509 -
750901 - CA 15-3 33 Cancer Marker Strong Response to Treatment Cetuximab
750902 -
750903 - Follow up ref SDS D6 GJ5M, ref SDS D3 GJ5M.
750905 -  ..
750906 - Patient history applying CA 15-3 is shown in a case study on 030710.
750907 - ref SDS 25 IA7H
750909 -  ..
750910 - Doctor Rugo was pleased by dramatic decline in CA 15-3 33, per above,
750911 - ref SDS 0 087J, since examination on 070301, when IBC rash was
750912 - expanding, and elevated cancer marker diagnostics seemed to indicate
750913 - failed treatment. ref SDS B8 464O  Examination today showing IBC rash
750914 - continues to subside, ref SDS 0 M68J, will be cross-checked with the
750915 - cancer marker for the blood test next week to start cycle 4.
750916 -
750917 -     [On 070426 CA 15-3 29 continues decline to lowest level of
750918 -     sustained indications for recovery, and aligns with continued
750919 -     decline of IBC rash intensity. ref SDS E1 GJ5M
750920 -
750921 -
750922 -
750923 -
750924 -
7510 -

SUBJECTS
Lymphadenopathy Axillary No Findings Left Arm Patient No Complaint S

8303 -
830401 -  ..
830402 - Axillary Left Arm No Lymphadenopathy Lymphedema Prominent
830403 - Lymphadenopathy Axillary Left Arm No Evidence Local Edema
830404 -
830405 - Follow up ref SDS D6 MW8J, ref SDS D3 MW8J.
830406 -
830407 - Patient has a long history of IBC on the left breast and associated
830408 - lymphadenopathy symptoms in the left axillary, see case study on
830409 - 040517. ref SDS 37 OW3I
830411 -  ..
830412 - Brigid examined the left axilla.  Clinical palpation made no findings
830413 - of lumps or other indications of cancer, including swelled lymph nodes
830414 - that might indicate lymphadenopathy.  The patient made no complaint of
830415 - lumps or discomfort from swelling under the left arm.  This aligns
830416 - with CT test on 070326 showing no findings of lymphadenopathy,
830417 - reported on 070329, ref SDS D3 12GK, although, there is no express
830418 - finding that the analyst actually looked at the left and right
830419 - axillary.
830420 -
830421 -
830422 -
8305 -

SUBJECTS
Lymphedema Swelling Persistent Left Arm Upper Erratic Intensity Rash

A103 -
A10401 -  ..
A10402 - Lymphedema Cellulitis Complications Left Arm Swelling
A10403 - Swelling Left Arm Lymphedema Cellulitis Complications
A10404 - Left Arm Lymphedema Cellulitis Complications Swelling Above Normal
A10405 - Cellulitis Lymphedema Complications Left Arm Swelling Above Normal
A10406 -
A10407 - Follow up ref SDS D6 4Y93, ref SDS D3 4Y93.
A10408 -
A10409 - Medical history of lymphedema in the left arm is reported in a case
A10410 - study on 070130. ref SDS B0 VX6F
A10412 -  ..
A10413 - The left arm today has continued swelling from lymphedema.  Recent
A10414 - measurement below the elbow was 11.25 inches, down slightly, but
A10415 - increased above previous norms reported in a study on 060509.
A10416 - ref SDS 78 HO7F
A10418 -  ..
A10419 - There wasn't enough time again today for discussing correlations
A10420 - between exercise to strengthen the immune system that resists cancer,
A10421 - and helps dissipate emotional stress, reviewed at UCSF on 070315,
A10422 - ref SDS C6 6A7J, but may compound lymphedema with increased swelling,
A10423 - and complications of Cellulitis, discussed at UCSF on 070222.
A10424 - ref SDS B6 GG4H  Lymphedema and Cellulitis in relation to side effects
A10425 - on the cetuximab clinical study are shown below. ref SDS D3 M84I
A10427 -  ..
A10428 - Brigid had reviewed Millie's letter on 070418, ref SDS D9 PZ3P,
A10429 - discussed, also, in connection with improved coordination, above,
A10430 - ref SDS 0 DI7M, and notifying UCSF that on 070330 the primary care
A10431 - physician at Kaiser observed significantly increased rash inflammation
A10432 - intensity on the upper left arm, ref SDS D6 N19J, and new inflammation
A10433 - of high intensity above the right breast and below the colar bone, per
A10434 - below. ref SDS 0 583G  Brigid was aware that at that time Millie had a
A10435 - slight fever of 99.4, ref SDS D6 7C8G, and that Kaiser prescribed
A10436 - Keflex medication to treat for Cellulitis, ref SDS D6 474O, but the
A10437 - rash subsided within a few hours after examination, and so Keflex
A10438 - medication was not taken. ref SDS D6 KZ6L
A10439 -
A10440 -     [On 070426 examination shows reduced IBC rash and no signs of
A10441 -     inflammation due to cetuximab side effects nor Cellulitis, cat
A10442 -     bite, etc. ref SDS E1 115F
A10444 -  ..
A10445 - Brigid examined the upper left arm today, and found intensity of
A10446 - inflammation has continued to subside, indicating response to
A10447 - treatment for IBC, which extends progress reported during examination
A10448 - on 070329, ref SDS D3 527G, as discussed below. ref SDS 0 527G  Doctor
A10449 - Rugo later made examination, and concurred that no change in treatment
A10450 - is required.
A10452 -  ..
A10453 - Millie asked about possibility that erratic inflammation on the left
A10454 - arm and upper right chest observed at Kaiser, and then subsided within
A10455 - a few hours, and not seen at UCSF today, might be side effects of
A10456 - cetuximab treatment for IBC, cited in the record meeting at UCSF on
A10457 - 070329? ref SDS D3 M84I  Jackie recalled that UCSF submitted a list of
A10458 - side effects from cetuximab treatments in a letter to Millie on
A10459 - 070116, as part of the clinical study consent documentation.
A10460 - ref SDS A7 RT7K
A10462 -  ..
A10463 - Review of cetuximab drug trial Consent showed...
A10464 -
A10465 -            Cetuximab causes skin reactions such as an acne-like rash,
A10466 -            drying, cracking, inflammation and infections. ref SDS A7
A10467 -            MH4Q
A10469 -  ..
A10470 - Millie sent a letter to UCSF the next day on 070117 requesting
A10471 - comments on issues presented by consent documents, ref SDS A8 HT3Q,
A10472 - and listed in the review on 070116.  One issue was cetuximab side
A10473 - effects in relation to Inflammatory Breast Cancer IBC. ref SDS A7 MH4Q
A10474 - On 070130 discussion at UCSF seemed to indicate that rash side effects
A10475 - from cetuximab only occur on the face. ref SDS B0 RN8O
A10477 -  ..
A10478 - Possibly inflammation and infection side effects of cetuximab could
A10479 - compound or otherwise intensify inflammation that occurs in skin
A10480 - infected with IBC?
A10481 -
A10482 -     [On 070426 examination shows reduced IBC rash and no signs of
A10483 -     inflammation due to cetuximab side effects nor Cellulitis, cat
A10484 -     bite, etc. ref SDS E1 115F
A10486 -  ..
A10487 - Brigid noted that research on the Internet, per below, ref SDS 0 D39M,
A10488 - indicates skin rash side effects of cetuximab only occur on the face,
A10489 - as discussed on 070130, and so cannot intensify IBC rash inflammation
A10490 - on the upper left arm, nor otherwise cause inflammation rash on the
A10491 - upper right chest observed at Kaiser on 070330, per above. ref SDS 0
A10492 - 115F
A10493 -
A10495 -  ..
A10496 - Redness Swelling Inflammation Side Effects Cetuximab
A10497 -
A10498 - Additional research on the Internet shows...
A10499 -
A10500 -        About Drug Finder
A10501 -        Cetuximab
A10502 -        Patient Education
A10503 -
A10504 -              http://gsm.about.com/compact/showtext.asp?cpnum=2710&monotype=full&gname=Cetuximab&r=6078
A10506 -         ..
A10507 -        Cetuximab commonly causes skin reactions including a rash that
A10508 -        looks like acne, skin dryness and cracking, redness, swelling
A10509 -        and other signs of inflammation that can result in skin
A10510 -        infections. These reactions may require treatment with
A10511 -        antibiotics.
A10513 -  ..
A10514 - This seems very close to language in the cetuximab Consent documents,
A10515 - per above, ref SDS 0 F57K, and could be interpretted to indicate that,
A10516 - besides acne-like rash on the face, in some cases cetuximab causes
A10517 - "redness, swelling, and other signs of inflammation," at locations
A10518 - other than the face, including observations at Kaiser on 070330 during
A10519 - examination of the upper left arm, ref SDS D6 N19J, and on the upper
A10520 - right chest, ref SDS D6 583G, as reported to UCSF on 070418, per
A10521 - above. ref SDS 0 115F
A10523 -  ..
A10524 - For example, on 070329 Millie reported cetuximab side effects of dry
A10525 - skin on the face, and also on the chest, arms, and back, which has
A10526 - been relieved with treatment prescribed by UCSF. ref SDS D4 JS6M
A10528 -  ..
A10529 - This record suggests that erratic rash observed at Kaiser could be a
A10530 - side effect of cetuximab treatment, but is unknown.  At this time, the
A10531 - rash has subsided, as occurred previously reported in Nurses Notes on
A10532 - 070315. ref SDS C6 KU3L
A10534 -  ..
A10535 - There was no discussion today of taking a biopsy to diagnose issues
A10536 - arrising from this rash, per below. ref SDS 0 KT7J
A10537 -
A10538 -
A10539 -
A10540 -
A10541 -
A106 -

SUBJECTS
Computer Examination Room Intelligence Support UCSF Internet Researc

AB03 -
AB0401 -  ..
AB0402 - Intelligence Support Computer Examination Room UCSF Internet Research
AB0403 - Computer Examination Room Intelligence Support UCSF Internet Research
AB0404 - UCSF Internet Research Computer Examination Room Intelligence Support
AB0405 -
AB0406 - During the meeting today, Brigid used the computer in the examination
AB0407 - room to check the Internet for cetuximab side effects.
AB0409 -  ..
AB0410 - Skills using computers to access Internet sources facilitate working
AB0411 - intelligently with precision access that strengthens coordination,
AB0412 - case management, and collaboration within the doctor/patient
AB0413 - partnership model, per above. ref SDS 0 DI9F
AB0414 -
AB0415 -
AB0416 -
AB0417 -
AB05 -

SUBJECTS
Cat Bite Symptoms Cancer Chemotherapy Case Study Fever Low Blood Cou

B503 -
B50401 -  ..
B50402 - Cat Bite Erratic Inflammation Fever Low Blood Counts
B50403 -
B50404 - Ruling out side effects of cetuximab, ref SDS 0 D39M, and also that
B50405 - rising inflammation is not rising IBC rash, per below, ref SDS 0 527G,
B50406 - may point to other trauma which has historically caused erratic rash
B50407 - and inflammation reactions, as occurred on Millie's upper left arm,
B50408 - along with slight fever found during examination at Kaiser on 070330,
B50409 - per above. ref SDS 0 115F
B50411 -  ..
B50412 - An example is cat bites.
B50414 -  ..
B50415 - Millie had a cat bite 3 - 4 weeks ago.  She had another cat bite a few
B50416 - days prior to examination at UCSF when no rash was observed, but was
B50417 - seen the next day at Kaiser on 070330.  Millie also suffered a
B50418 - household accident cutting herself with a small knife preparing dinner
B50419 - during this period.  At least one of these incidents took a matter of
B50420 - hours to stop bleeding, though the rate was very mild, and so medical
B50421 - assitance was not requested.  Prolonged bleeding may reflect treatment
B50422 - for pulmonary embolism with Coumadin.
B50423 -
B50424 -     [On 070426 examination shows reduced IBC rash and no signs of
B50425 -     inflammation due to cetuximab side effects nor Cellulitis, cat
B50426 -     bite, etc. ref SDS E1 115F
B50428 -      ..
B50429 -     [On 070612 Millie suffered another cat bite while recovering from
B50430 -     Cellulitis and fever. ref SDS E4 6G7N
B50432 -  ..
B50433 - Patient history shows cat bites while getting chemotherapy have caused
B50434 - delayed Cellulitis-like symptoms of temperature, inflammation,
B50435 - swelling, low blood counts, and pain, including hospitalization...
B50436 -
B50437 -        1.  Cellulitis treated Emergency Room
B50438 -            rash spreads above left brast toward
B50439 -            neck, elevated temperature diagnosed
B50440 -            side effect of medication prescribed
B50441 -            to treat wound from punch biopsy
B50442 -            on 040419 to diagnose IBC, and had
B50443 -            gotten worse with rise of IBC
B50444 -            after ending treatment on
B50445 -            041104............................. 041202, ref SDS 49 0001
B50447 -             ..
B50448 -        2.  Cat bite right hand, emergency
B50449 -            treatment, hospitalized 4 days
B50450 -            temperature, swelling,
B50451 -            pain in arm........................ 050212, ref SDS 54 0001
B50453 -             ..
B50454 -            Inflammation, low blood counts,
B50455 -            fever.............................. 050212, ref SDS 54 I34W
B50457 -             ..
B50458 -        3.  Broken finger left hand on 060914
B50459 -            diagnosed in emergency room as
B50460 -            causing Cellulitis 6 weeks later
B50461 -            with elevated temperature, and
B50462 -            severe swelling and inflammation
B50463 -            entire left
B50464 -            arm................................ 061027, ref SDS 94 0001,
B50466 -             ..
B50467 -        4.  Cellulitis relapse following cat
B50468 -            bite 2 weeks earlier............... 061203, ref SDS 97 MF9H
B50469 -            left arm swollen, inflammation,
B50470 -            fatigue, slight
B50471 -            temperature........................ 061203, ref SDS 97 5X3N
B50473 -             ..
B50474 -        5.  Cat bite inflammation upper left
B50475 -            arm IBC rash upper right chest
B50476 -            below collar bone infection above
B50477 -            port catheter upper right
B50478 -            chest.............................. 061203, ref SDS 0 P67J
B50480 -             ..
B50481 -        6.  Cat bites in March may cause erratic
B50482 -            inflammation and fever compounding
B50483 -            side effects of cetuximab
B50484 -            treatments at UCSF................. 070419, ref SDS 0 P67J
B50486 -             ..
B50487 -        7.  Cat bites in March and April may have
B50488 -            caused delayed reaction sudden reversal
B50489 -            and falling blood counts below the
B50490 -            level of safety for receiving
B50491 -            treatments......................... 070426, ref SDS E1 G23M
B50493 -  ..
B50494 - As a precaution, more related to investigating a new blemish on the
B50495 - right side of the chest above the port catheter, the doctor ordered an
B50496 - interim blood test today, mostly to perform a culture study on the
B50497 - port catheter, discussed further below. ref SDS 0 583G
B50498 -
B50499 -
B50500 -
B50501 -
B50502 -
B50503 -
B506 -

SUBJECTS
IBC Left Arm Examination Stable Subsides Rash Less Intense Responds

BJ03 -
BJ0401 -  ..
BJ0402 - IBC Left Arm Stable Subsiding Responds Treatment Cetuximab Drug Trial
BJ0403 - Left Arm IBC Stable Subsiding Responds Treatment Cetuximab Drug Trial
BJ0404 -
BJ0405 - Follow up ref SDS D6 527G, ref SDS D3 527G.
BJ0406 -
BJ0407 - There was no evidence today of increased rash intensity on the upper
BJ0408 - left arm, as observed at Kaiser on 070330, and diagnosed at that time
BJ0409 - as Cellulitis, per above. ref SDS 0 115F  Research today indicating
BJ0410 - redness and inflammation are, also, side effects of cetuximab, which
BJ0411 - may cause short term compounding appearance of rash on the upper left
BJ0412 - arm, without progression of IBC, per above. ref SDS 0 RA5F  As well,
BJ0413 - Millie suffered a cat bite within the past month or so.  Patient
BJ0414 - history shows erratic changes in inflammation, and temperature due to
BJ0415 - infection, that may compound appearance of IBC rash. ref SDS 0 P67J
BJ0416 - Falling CA 15-3 cancer marker, and appearance of subsiding IBC rash
BJ0417 - today, support conclusion other factors caused short-term increase of
BJ0418 - intensity on 070330 for IBC rash on upper left arm observed at Kaiser.
BJ0419 - Doctor Rugo and the medical team at Kaiser have done an excellent job
BJ0420 - addressing "wicked problems" presented by multiple diagnosis issues,
BJ0421 - discussed further below. ref SDS 0 VF5M
BJ0423 -  ..
BJ0424 - Examination today indicates the size of IBC rash on the upper left arm
BJ0425 - has been stable, and intensity stable to subsiding, i.e., improving by
BJ0426 - responding to treatment, since the prior examination at UCSF on
BJ0427 - 070329. ref SDS D3 527G
BJ0429 -  ..
BJ0430 - Aligns with declining measurable disease cancer marker CA 15-3, per
BJ0431 - above. ref SDS 0 UZ8N
BJ0433 -  ..
BJ0434 - Since today does not start a new treatment cycle, per above,
BJ0435 - ref SDS 0 SM6M, Jackie did not take photographs for measurable
BJ0436 - disease.   She explained photographs will be taken next week to begin
BJ0437 - cycle 4.
BJ0438 -
BJ0439 -
BJ0440 -
BJ05 -

SUBJECTS
Right Axillary Lymphadenopathy No Findings Right Arm Patient No Comp

BR03 -
BR0401 -  ..
BR0402 - Right Axillary Possible Involvement Red Rash Spreads Right Breast
BR0403 -
BR0404 - Follow up ref SDS D6 3D6K, ref SDS D3 3D6K.
BR0405 -
BR0406 - Background on patient history testing for lymphadenopathy in the right
BR0407 - axilla is reported in the record on 060929. ref SDS 90 3D6K
BR0409 -  ..
BR0410 - Examination of the right axillary yielded same negative results
BR0411 - finding no evidence of lymphadenopathy, as occurred examining the left
BR0412 - axilla, per above. ref SDS D3 VU6O  Also aligns with CT test on
BR0413 - 070326, reviewed on 070329. ref SDS D3 12GK
BR0414 -
BR0415 -
BR0416 -
BR0417 -
BR05 -

SUBJECTS
Right Arm Examination Rash Slight Blemishes No Evidence IBC No Findi

BY03 -
BY0401 -  ..
BY0402 - IBC Right Arm New Minimal Red Rash Not Diagnosed IBC or Cellulitis
BY0403 -
BY0404 - Follow up ref SDS D6 H15M, ref SDS D3 H15M.
BY0405 -
BY0406 - Background on slight red dots, rash or blemishes on the right arm is
BY0407 - reported on 070301. ref SDS B8 H15M  Examination at that time
BY0408 - concluded the rash is not IBC.  Further examination on 070315 reached
BY0409 - the same conclusion, ref SDS C6 FO6H, supported by another review on
BY0410 - 070322. ref SDS C7 LI4M
BY0412 -  ..
BY0413 - Examination today yielded no change in analysis that IBC has not
BY0414 - spread to the right arm, and Cellulitis has not occurred in the right
BY0415 - arm.  Similarly, there is no evidence of side effects in the right arm
BY0416 - from cetuximab treatment for IBC, reported on 070329. ref SDS D3 MF6I
BY0417 -
BY0418 -
BY0419 -
BY0420 -
BY0421 -
BY05 -

SUBJECTS
IBC Right Breast Examination Stable Subsides Rash Less Intense Respo

C703 -
C70401 -  ..
C70402 - Right Breast Red Rash Spreads Possible Involvement Right Axillary
C70403 - Red Rash Right Breast Spreads Possible Involvement Right Axillary
C70404 -
C70405 - Follow up ref SDS D6 W58J, ref SDS D3 T99I.
C70407 -  ..
C70408 - On 061204 IBC inflammation spread from the left chest area infected
C70409 - with IBC across the sternum and slightly onto the right breast.
C70410 - ref SDS 98 AE5I  Since that time, IBC rash has spread no further.  It
C70411 - became more intense through January, and then intensity of the rash
C70412 - has continued to subside with treatment.
C70414 -  ..
C70415 - Examination of right breast today shows reduced intensity of IBC rash,
C70416 - and there is no spreading of the rash, suggesting favorable response
C70417 - to treatment.  Declining CA 15-3 33 cancer marker reported today for
C70418 - the blood test on 070329, per above, ref SDS 0 087J, aligns with
C70419 - visual impression today of subsiding IBC.
C70421 -  ..
C70422 - Since today does not start a new treatment cycle, per above,
C70423 - ref SDS 0 SM6M, Jackie did not take photographs for measurable
C70424 - disease.   She explained photographs will be taken next week to begin
C70425 - cycle 4.
C70426 -
C70427 -
C70428 -
C70429 -
C70430 -
C705 -

SUBJECTS
Rash Chest Right Side Above Breast Below Collar Bone Above Port Cath

CH03 -
CH0401 -  ..
CH0402 - Right Chest Rash Not Visible Above Breast and Port Catheter
CH0403 - Rash Above Port Catheter on Right Upper Chest Not Visible Today
CH0404 -
CH0405 - Follow up ref SDS D6 583G, ref SDS D3 583G.
CH0406 -
CH0407 - Nurse's Notes for treatment on 070315 in the Infusion Clinic report
CH0408 - rash above the port catheter on the right side of the chest, and well
CH0409 - above the right breast, just below the collar bone.  This condition
CH0410 - was not previously reported at Kaiser nor UCSF.  Following review of
CH0411 - Nurse's Notes, there was no evident rash observed by the patient.
CH0412 - ref SDS C6 KU3L  A week later, on 070322 Nurse's Notes for treatment
CH0413 - report no continuing inflammation at this location. ref SDS C7 KU3L
CH0415 -  ..
CH0416 - Case study on 070130 shows erratic changes in severity/intensity of
CH0417 - IBC rash on the left chest area, which led to referral to UCSF.
CH0418 - ref SDS B0 5N6L  Possible correlation with cat bites with rash and
CH0419 - fever are listed in a case study, above. ref SDS 0 P67J
CH0421 -  ..
CH0422 - This morning, Brigid had reviewed Millie's letter on 070418,
CH0423 - ref SDS D9 PZ3P, and was prepared to discuss the approximate 2" x 1"
CH0424 - oval red rash on the right chest and just below the collar bone that
CH0425 - was observed during examination at Kaiser on 070330, along with
CH0426 - increased intensity of inflammation on the left arm, and which had
CH0427 - fully subsided, i.e., was no longer visible on the right chest, within
CH0428 - a few hours, per above. ref SDS 0 115F
CH0430 -  ..
CH0431 - Like examination of the left arm finding no increased rash intensity,
CH0432 - also, per above, ref SDS 0 116J, examination today observed no
CH0433 - identifiable rash or inflammation above the port catheter area and
CH0434 - below the collar bone on the right chest.  Skin coloration and texture
CH0435 - appear normal today in all respects, similar to the left arm that now
CH0436 - appears "normal" for mild IBC rash that was diagnosed on 070222, and
CH0437 - observed again this morning to have subsiding intensity, per above.
CH0438 - ref SDS 0 116J
CH0440 -  ..
CH0441 - Erratic rash on the upper right chest, first observed by the nurse on
CH0442 - 070315, and then again 2 weeks later at Kaiser on 070330, and quickly
CH0443 - subsided presents possibility that cetuximab side effects of redness
CH0444 - and inflammation were factors, as discussed above, ref SDS 0 F57K,
CH0445 - including research on the Internet that Brigid did during the meeting
CH0446 - today, ref SDS 0 D39M, along with post-meeting supplemental research,
CH0447 - also, listed above. ref SDS 0 RA5F
CH0449 -  ..
CH0450 - Cetuximab side effects are further discussed below. ref SDS 0 TQ6L
CH0452 -  ..
CH0453 - There was no discussion today of taking a biopsy to diagnose issues
CH0454 - arrising from this rash, per below. ref SDS 0 KT7J
CH0455 -
CH0456 -
CH0457 -
CH0458 -
CH0459 -
CH05 -

SUBJECTS
Right Chest Blemish Port Catheter .75" Above Infection .5" Diameter

CU03 -
CU0401 -  ..
CU0402 - Port Catheter Infection Blemish Right Chest Blood Culture Investigate
CU0403 -
CU0404 - Follow up ref SDS D3 BI5K.
CU0405 -
CU0406 - Today the entry to the port catheter shows mild inflammation that
CU0407 - appears like a skin blemish, but seems more prominent today than
CU0408 - usual.
CU0409 -
CU0410 -     [On 070426 Nurse's Notes for treatment in the Infusion Clinic note
CU0411 -     redness at the port site. ref SDS E2 LX7H
CU0413 -  ..
CU0414 - The doctor further noticed during the examination an approximate .5"
CU0415 - diameter blemish, rash or inflammation of the skin centered about .75"
CU0416 - directly above the port catheter, and perhaps .75" to the right of the
CU0417 - inflammation below the collar bone discussed above. ref SDS 0 FE5O
CU0419 -  ..
CU0420 - Observations today align with examination on 070329.  At that time,
CU0421 - Brigid reported a few blemishes on the right chest with reddish
CU0422 - coloration. ref SDS D3 BI5K
CU0424 -  ..
CU0425 - Considerations of cetuximab side effects that cause infection,
CU0426 - redness, and inflammation were not discussed, per above discussing
CU0427 - previous observations of inflammation on left arm, ref SDS 0 F57K,
CU0428 - similar to not discussing erratic rash to skin area left of this
CU0429 - blemish, per above. ref SDS 0 583G
CU0431 -  ..
CU0432 - Cetuximab side effects are further discussed below. ref SDS 0 TQ6L
CU0434 -  ..
CU0435 - There was no discussion today of taking a biopsy to diagnose issues
CU0436 - arrising from this rash/inflammation/infection, per below. ref SDS 0
CU0437 - KT7J
CU0439 -  ..
CU0440 - The port was installed at Kaiser on 040419 to start treatments with
CU0441 - bevacizumab on the Avastin clinical drug trial. ref SDS 35 0001
CU0443 -  ..
CU0444 - Since the port is accessed once a week, prolonged use and frequency
CU0445 - may be causing slight irritation or infection that presents mild and
CU0446 - small areas of redness and inflammation.  The doctor noted that the
CU0447 - other, now, .5" blemish above the port has no evident explanation.
CU0449 -  ..
CU0450 - FDA reports side effects of cetuximab include skin inflammation and
CU0451 - infection, per below. ref SDS 0 WR4O
CU0453 -  ..
CU0454 - Consideration might be given to notifying the surgeon, who installed
CU0455 - the port, for comments and examination.
CU0457 -  ..
CU0458 - Millie asked if the blemish above the port catheter could be part of
CU0459 - the port catheter that runs beneath the skin toward the neck, and for
CU0460 - some reason shows irritation only at this isolated location?  The tube
CU0461 - from the port catheter is evident to the touch that connects the
CU0462 - entery point to the blemish .75" above.  Might this other blemish that
CU0463 - this week has increased slightly with inflammation be another
CU0464 - manifestation of cetuximab side effects that cause skin redness and
CU0465 - inflammation, per research above? ref SDS 0 RA5F
CU0467 -  ..
CU0468 - Doctor Rugo ordered a "culture" to investigate this issue.
CU0470 -  ..
CU0471 - Brigid prepared an order for a blood test, which Millie hand carried
CU0472 - to the Infusion Clinic after the examination, reported in another
CU0473 - record.  Results of the blood test did not diagnose a medical problem
CU0474 - that requires treatment.  Millies blood counts show continued
CU0475 - improvement with NEUTS rising to 1.87 (ANC - 1870), per below.
CU0476 - ref SDS 0 VF5M
CU0477 -
CU0478 -    [On 070426 no evident inflammation at this location; problem
CU0479 -    resolved itself without treatment; UCSF reported results of blood
CU0480 -    culture were negative. ref SDS E2 UJ4M
CU0482 -  ..
CU0483 - Later in the day, the .5" diameter rash above the port subsided to
CU0484 - more of a small blemish, or large "dot." Over the next day this nearly
CU0485 - disappeared, similar to the rash below the collar bone that appeared
CU0486 - on 070330 and then completely disappeared within a few hours, per
CU0487 - above. ref SDS 0 FE5O
CU0488 -
CU0489 -
CU0490 -
CU0491 -
CU0492 -
CU05 -

SUBJECTS
Left Supraclavicular Examination Palpation Neck Lymphadenopathy No F

D203 -
D20401 -  ..
D20402 - Left Supraclavicular Examination PET Test Report Finding SUV 4.5
D20403 - Prognosis Stage IV Metastatic Disease Relapse IBC Seems Likely
D20404 - Lumps in Neck Reported 040309 Establish Stage IV Metastatic Cancer
D20405 -
D20406 - Follow up ref SDS D6 8R6M, ref SDS D3 8R6M.
D20407 -
D20408 - During examination on 070130, Doctor Rugo asked about history of
D20409 - radiation to the neck, and sequence of finding recurrence from Doctor
D20410 - Laio's biopsy reported on 040309. ref SDS 29 0001  Background of image
D20411 - testing, and consideration for radiation treatment of left
D20412 - supraclavicular is reported on 060623. ref SDS 81 8R6M
D20414 -  ..
D20415 - Like the left and right axillary locations, examination today for
D20416 - cancer in left supraclavicular region found no evidence of lumps or
D20417 - other indications of lymphadenopathy, as reported above. ref SDS 0
D20418 - VU6O  CT test on 070326 shows no findings of lymphadenopathy, reported
D20419 - during examination on 070329. ref SDS D3 12GK  There is no express
D20420 - finding in the CT test report that the analyst actually looked at the
D20421 - left and right supraclavicular.
D20422 -
D20423 -
D20424 -
D205 -

SUBJECTS
IBC Left Breast Examination 2 Scenarios End Stable Area No New Sites

DJ03 -
DJ0401 -  ..
DJ0402 - 2 Scenarios Conflict IBC Expanding Intensity Subsides
DJ0403 - IBC Rash Left Breast Stomach and Back Seems to Be Subsiding
DJ0404 - Examination IBC Rash Subsiding Responding to Treatment Cetuximab
DJ0405 - Cetuximab Effective Treatment IBC Subsiding Left Breast Stomach Back
DJ0406 -
DJ0407 - Follow up ref SDS D6 025H, ref SDS D3 025H.
DJ0408 -
DJ0409 - Background of IBC 3rd relapse on left breast beginning on 060623, and
DJ0410 - treatment with Taxotere and capecitabine ending on 061201, with
DJ0411 - subsequent progression of disease spreading to other areas is reported
DJ0412 - on 070301. ref SDS B8 025H
DJ0414 -  ..
DJ0415 - Case study on 070130 shows erratic changes in severity/intensity of
DJ0416 - IBC rash on left chest area, with referral to UCSF. ref SDS B0 5N6L
DJ0418 -  ..
DJ0419 - All case studies for Millie's patient history are listed on 061018.
DJ0420 - ref SDS 92 0001
DJ0422 -  ..
DJ0423 - Cetuximab treatment started at UCSF on 070201. ref SDS B2 G68I
DJ0425 -  ..
DJ0426 - Strategy for treating progression of disease was reviewed on 070301.
DJ0427 - ref SDS B8 1T4O
DJ0429 -  ..
DJ0430 - Examination today shows intensity of IBC rash continues to subside or
DJ0431 - remains stable, and there is no evident expansion of IBC rash areas,
DJ0432 - and further there are no new IBC rash sites, as listed on 070301.
DJ0433 - ref SDS B8 4140  The current condition today is...
DJ0434 -
DJ0435 -            left breast chest................. 060623, ref SDS 81 025H
DJ0436 -            right breast...................... 061204, ref SDS 98 AE5I
DJ0437 -            stomach........................... 070130, ref SDS B0 M68J
DJ0438 -            back.............................. 070130, ref SDS B0 M68J
DJ0439 -            left arm.......................... 070202, ref SDS B3 6Q5N
DJ0441 -  ..
DJ0442 - Examination today further shows that scattered sprinkles of rash
DJ0443 - diagnosed on 070130 as IBC on the stomach and back, ref SDS B0 M68J,
DJ0444 - have nearly disappeared after 3 cycles of treatment with cetuximab.
DJ0446 -  ..
DJ0447 - The doctor feels that erratic increase of inflammation intensity on
DJ0448 - the upper left arm infected with IBC rash does not represent
DJ0449 - progression of disease, per above, ref SDS 0 527G,
DJ0451 -  ..
DJ0452 - On 070330 primary care physician at Kaiser comments on how well Millie
DJ0453 - looks, ref SDS D6 N49K, reflecting similar report at UCSF the previous
DJ0454 - day on 070329.
DJ0456 -  ..
DJ0457 - On 070418 Millie notified UCSF with copy to Kaiser that she cannot
DJ0458 - remember feeling better. ref SDS D9 PY6W
DJ0459 -
DJ0460 -
DJ0461 -
DJ0462 -
DJ05 -

SUBJECTS
Prognosis Stable Low Intensity IBC Rash Very Good Response Treatment

DQ03 -
DQ0401 -  ..
DQ0402 - Prognosis Very Good IBC Stable Cetuximab Clinical Study
DQ0403 - Stable Low Intensity IBC Rash Very Good Response to Treatment
DQ0404 - Cetuximab Prognosis Good Chance IBC Rash 3rd Relapse Will Clear Up Again
DQ0405 -
DQ0406 - Follow up ref SDS D6 M645, ref SDS D3 M645.
DQ0408 -  ..
DQ0409 - IBC conditions of subsiding intensity and no new disease sites,
DQ0410 - together with favorable CT test reported on 070329, ref SDS D3 LV57,
DQ0411 - and falling cancer marker, per above, ref SDS 0 WU6J, indicate that
DQ0412 - treatment with cetuximab alone seems effective at this time, as
DQ0413 - predicted by Doctor Rugo on 070130. ref SDS B0 M645
DQ0414 -
DQ0415 -
DQ0416 -
DQ0417 -
DQ0418 -
DQ05 -

SUBJECTS
Distant Metastasis No Evidence 6 Years Patient History Examinations

DY03 -
DY0401 -  ..
DY0402 - Distant Metastasis No Evidence Patient History Examinations Tests
DY0403 - Local IBC Infection No Record Distant Metastasis Improves Chances
DY0404 - Prognosis Favorable No Lymphadenopathy 2006 No Distant Metastasis 5 Years
DY0405 -
DY0406 - Follow up ref SDS D6 FF4H, ref SDS D3 FF4H.
DY0407 -
DY0408 - The doctor concurred today with assessment at Kaiser during the
DY0409 - meeting on 070330, ref SDS D6 FF4H, citing CT test on 070326 showing
DY0410 - no evidence of distant metastasis, reviewed on 070329. ref SDS D3 LV57
DY0411 - Further alignment with patient history showing no reports of distant
DY0412 - metastasis in all image tests for over 5 years. ref SDS D3 DA8O
DY0413 -
DY0414 -
DY0415 -
DY0416 -
DY05 -

SUBJECTS
Wicked Problem Erratic Inflammation Rash Left Arm Right Chest Could

EL03 -
EL0401 -  ..
EL0402 - Wicked Problem Resolved Disease Subsides ANC Rises to Safe Level
EL0403 - ANC 1.87 Blood Counts Rise Above Safe Level for Treatment with Cetuximab
EL0404 -
EL0405 - Follow up ref SDS D6 VF5M, ref SDS D3 VF5M.
EL0406 -
EL0407 - Millie had a blood test this morning during treatment at 0830 in the
EL0408 - Infusion Clinic, ordered by the doctor to evaluate blemish and
EL0409 - possible infection inflammation both at and above the port catheter on
EL0410 - the right chest, per above. ref SDS 0 L55J
EL0412 -  ..
EL0413 - Test results show blood counts for NEUTS rising to 1.87 (ANC = 1870 by
EL0414 - Kaiser criteria), which demonstrates further resolution of prior
EL0415 - "wicked problem," as reported on 070329, ref SDS D3 VF5M, and
EL0416 - discussed at Kaiser the next day on 070330. ref SDS D6 VF5M
EL0418 -  ..
EL0419 - Erratic inflammation and rash on upper left arm presents a "wicked
EL0420 - problem" of diagnosis, explained on 060722. ref SDS 84 346F  UCSF has
EL0421 - used integrated strategy of CT tests, and CA 15-3 cancer marker trend
EL0422 - analysis in combination with clinical examinations and photographic
EL0423 - measurement to distinguish multiple causes of common symptoms...
EL0424 -
EL0425 -    1.  IBC progression of disease..................... ref SDS 0 527G
EL0426 -    2.  Cellulitis complications lymphedema............ ref SDS 0 4Y93
EL0427 -    3.  Cetuximab side effects inflammation redness.... ref SDS 0 F57K
EL0428 -    4.  Cat bite....................................... ref SDS 0 P67J
EL0429 -
EL0430 -
EL0431 -
EL0432 -
EL0433 -
EL0434 -
EL05 -

SUBJECTS
Measurable Disease IBC CA 15-3 33 Cancer Marker Improves Shows Respo

EZ03 -
EZ0401 -  ..
EZ0402 - Measurable Disease IBC No New Sites No Expansion Intensity Declines
EZ0403 - Photographs Record Measurable Disease IBC Tumor in Dermal Tissue
EZ0404 - Measurable Disease IBC Observed with Tape Measure Photograph Pictures
EZ0405 - CA 15-3 Diagnostic Measurable Disease IBC Not Measured by Image Testing
EZ0406 -
EZ0407 - Follow up ref SDS D6 M652, ref SDS D3 M652.
EZ0408 -
EZ0409 - Measurements and pictures will be taken next week to start the next
EZ0410 - cycle, per planning last week on 070412. ref SDS D8 FO6H
EZ0411 -
EZ0412 -
EZ0413 -
EZ0414 -
EZ05 -

SUBJECTS
Lung Cancer No Discussion Metastatic Disease Nodes Doctor's Progress

FA03 -
FA0401 -  ..
FA0402 - Lung Cancer Lymph Nodes Doctor's Progress Notes Medical Chart
FA0403 - Metastatic Cancer Lung Lymph Node Progress Notes Medical Chart
FA0404 -
FA0405 - Follow up ref SDS D6 G25K, ref SDS D3 G25K.
FA0406 -
FA0407 - Background is reported on 070130 in the record meeting with Doctor
FA0408 - Rugo at UCSF. ref SDS B0 G25K  Findings for the most recent CT test on
FA0409 - 070326 do not support concern about lung cancer shown in Kaiser's
FA0410 - Medical Chart on 061208, ref SDS 99 G25K, and, finding no
FA0411 - "interstitial disease" further indicates this side effect of cetuximab
FA0412 - treatment has not occurred in Millie's case so far, reported on
FA0413 - 070329. ref SDS D3 123I  Interstitial lung disease was listed in the
FA0414 - clincial study Consent documents received from UCSF on 070116.
FA0415 - ref SDS A7 0256
FA0417 -  ..
FA0418 - There was no discussion of this issue today, so that attention could
FA0419 - focus on assessing Millie's response to treatment for IBC.
FA0420 -
FA0421 -
FA0422 -
FA0423 -
FA05 -

SUBJECTS
Biopsy Left Right Breasts Left Arm Right Chest Erratic Changes Inten

FH03 -
FH0401 -  ..
FH0402 - Biopsy Erratic Changes Rash Intensity Verify IBC Left Arm
FH0403 -
FH0404 - Follow up ref SDS D6 KT7J, ref SDS D3 KT7J.
FH0405 -
FH0406 - Background on biopsy to diagnose erratic rash on left and right chest
FH0407 - is reported in the record on 070130. ref SDS B0 KT7J  On 070202 a new
FH0408 - rash was observed on the upper left arm, ref SDS B3 JP6F, which has
FH0409 - since been considered expanding IBC, reported on 070222. ref SDS B6
FH0410 - B643  This new rash on the left arm has not been verified by biopsy,
FH0411 - as reported on 070202. ref SDS B3 JP6L  More recently consideration of
FH0412 - possible rash on right arm is reported on 070301. ref SDS B8 KT7J
FH0414 -  ..
FH0415 - There was no discussion today of taking biopsies to verify diagnosis
FH0416 - of rash on the left arm, discussed on 070301, ref SDS B8 527G, and
FH0417 - reported to present increased intensity during examination at Kaiser
FH0418 - on 070330, per above. ref SDS 0 115F  At that time on 070330 diagnosis
FH0419 - of Cellulitis was made and treatment prescribed without biopsy.
FH0420 - ref SDS D6 Z23K  Similarly, there was no discussion of taking a biopsy
FH0421 - to test the 2" x 1" oval area of rash reported in Nurses Notes for
FH0422 - treatment on 070315, and observed again at Kaiser on 070330,
FH0423 - ref SDS D6 DH6F, also, per above. ref SDS 0 583G
FH0425 -  ..
FH0426 - The doctor ordered a blood culture to assess the blemish above the
FH0427 - port catheter, per above, ref SDS 0 Q57J, and findings were negative,
FH0428 - so this method did not identify the cause of this new issue.
FH0430 -  ..
FH0431 - Previously, on 040419 biospy was successful in this case identifying
FH0432 - unknown rash on the left breast, that had stumped investigators for
FH0433 - over a year, reported 040517. ref SDS 37 6T5G  Doctor Benz noted in a
FH0434 - second opinon consultation at UCSF on 060815 that biopsy is effective
FH0435 - for diagnosing medical problems. ref SDS 88 KT7J
FH0436 -
FH0437 -
FH0438 -
FH0439 -
FH05 -

SUBJECTS
Emotional Trauma Stress Moderate Pulse Normal Cancer Subsides Confid

FT03 -
FT0401 -  ..
FT0402 - Emotional Trauma Rising Falling Cancer Symptoms Risks Image Testing
FT0403 - Exercise Vigor Strength Engagement Ease Distress Living with Cancer
FT0404 - Behavior Medical Specialist (BMS) Emotional Counseling Not Effective
FT0405 -
FT0406 - Follow up ref SDS D6 Y642, ref SDS D3 Y642.
FT0407 -
FT0408 - Medical issues create an emotional roller coaster explained on 070105,
FT0409 - ref SDS A5 Y642, and reviewed on 070301. ref SDS B8 Y642  Stress and
FT0410 - trauma are compounded with rising complexity of case history, listed
FT0411 - above. ref SDS 0 LU3J
FT0413 -  ..
FT0414 - Improved medical prognosis, ref SDS 0 M645, and better coordination,
FT0415 - ref SDS 0 CQ6J, relieve stress reflected in Millie's vitals that are
FT0416 - calmer today, e.g., pulse below 60, ref SDS 0 KB5L, and reported in
FT0417 - patient history for treatment after examination. ref SDS E0 AW4L
FT0418 -
FT0419 -
FT0420 -
FT0421 -
FT0422 -
FT0423 -
FT05 -

SUBJECTS
Sleeping Difficulty subsides Worry Emotional Trauma Stress Prognosis

G503 -
G50401 -  ..
G50402 - Sleeping Difficulty Subsides Health Issues Medical Management Improve
G50403 -
G50404 - Follow up ref SDS D6 MR99, ref SDS D3 NG3I.
G50405 -
G50406 - Sleeping difficulties have subsided the past few weeks.
G50407 -
G50408 -
G50409 -
G505 -

SUBJECTS
Strategy 3 Issues Resolved Sucessfully Work Plan Continue Weekly Tre

GA03 -
GA0401 -  ..
GA0402 - Planning Case Management from Patient Profile Work Up
GA0403 - Work Up Patient Profile Develop Options Strategy Treatment IBC Relapse
GA0404 - Strategy Cetuximab Continued with Low ANC Expanding IBC Disease
GA0405 -
GA0406 - Follow up ref SDS D6 K36G, ref SDS D3 K36G.
GA0407 -
GA0408 - Background is reported on 070301. ref SDS B8 K36G  Coordination issues
GA0409 - are presented above. ref SDS 0 RM4G
GA0411 -  ..
GA0412 - There are three (3) strategy issues...
GA0413 -
GA0414 -        1.  Find new treatments as disease progresses.
GA0415 -        2.  Aggressive treatment IBC distinguish from other issues.
GA0416 -        3.  Aggressive treatment by monitoring side effects of
GA0417 -            lung and heart disease.
GA0419 -  ..
GA0420 - Millie is fortunate the doctor can plan on adding carboplatin to
GA0421 - strengthen current treatment, if disease progresses with only
GA0422 - cetuximab, per above. ref SDS 0 Q65N  On 070130 the doctor plans to
GA0423 - consider another treatment with Avastin, if needed later after the
GA0424 - clinical study for cetuximab and carboplatin. ref SDS B0 LD64
GA0426 -  ..
GA0427 - Doctor Rugo developed a strategy on 070130 to reduce risks of blood
GA0428 - clots and heart attacks presented by cetuximab treatments, reported on
GA0429 - 070116 in Clinical Study Consent documents for participating in the
GA0430 - drug trial at UCSF. ref SDS A7 I75I  Millie's patient history of
GA0431 - recurrent pulmonary embolism, and heart disorders (Cor Pulmonale)
GA0432 - diagnosed in CT test on 060930, and reviewed on 061012, ref SDS 91
GA0433 - 294Q, requires effective strategy to manage life threatening risks
GA0434 - compounded by cetuximab treatments.  At that time on 070130, the
GA0435 - doctor cited Millie's family history as an additional risk factor.
GA0436 - ref SDS B0 LD6Y  The doctor's strategy on 070130 called for thin slice
GA0437 - spiral CT testing to assess progression of lung and heart disease with
GA0438 - cetuximab treatments. ref SDS B0 R16N
GA0440 -  ..
GA0441 - On 070330 the primary care physician noted that the CT scan on 070326
GA0442 - did not implement the UCSF strategy to test for blood clots and heart
GA0443 - disorder, ref SDS D6 XW5N, discussed further below. ref SDS 0 CV5L
GA0445 -  ..
GA0446 - UCSF strategy to assess progression of IBC disease with CT tests, CA
GA0447 - 15-3 cancer marker, and clinical examination has been effective
GA0448 - resolving "wicked problem" distinguishing multiple forms of rash and
GA0449 - inflammation observed today, per above. ref SDS 0 S57H
GA0450 -
GA0451 -
GA0452 -
GA0453 -
GA0454 -
GA0455 -
GA0456 -
GA05 -

SUBJECTS
Treatment IBC 10th Cycle 3rd Relapse 3rd Cycle 4th Treatment Chemoth

GF03 -
GF0401 -  ..
GF0402 - Treatment 3rd Cycle Cetuximab Carboplatin 070329 10th Cycle 3rd Relapse
GF0403 - 10th Cycle Treatment IBC 3rd Relapse 3rd Cycle Cetuximab Clinical Study
GF0404 - Cetuximab 3rd Cycle 1st Treatment IBC 3rd Relapse Clinical Study Drug Trial
GF0405 -
GF0406 - Follow up ref SDS D6 PF3O, ref SDS D3 PF3O.
GF0407 -
GF0408 - Patient history of cetuximab treatments is listed in the record on
GF0409 - 070419 working with the Infusion Clinic. ref SDS E0 7T3H
GF0411 -  ..
GF0412 - Following examination in the Breast Care Center, Millie received
GF0413 - treatment at 0930 with pre-treatment Benadryl, ref SDS E0 DC7J, and at
GF0414 - 1000 with cetuximab on clincial study, reported in another record.
GF0415 - ref SDS E0 4N5M
GF0417 -  ..
GF0418 - Jackie advised that patients can no longer be treated with cetuximab
GF0419 - alone, per above. ref SDS 0 Q65N
GF0421 -  ..
GF0422 - Treatment of blemishes on the port catheter will be assessed after
GF0423 - results of the culture from the blood test are reported later today,
GF0424 - per above. ref SDS 0 S640
GF0426 -  ..
GF0427 - Since increased intensity of IBC rash on the upper left arm, and on
GF0428 - the right chest below the collar bone subsided after meeting with the
GF0429 - doctor on 070330, and have not further appeared, per above,
GF0430 - ref SDS 0 115F, no treatment was prescribed today.
GF0431 -
GF0432 -
GF0433 -
GF0434 -
GF0435 -
GF05 -

SUBJECTS
Side Effects Cetuximab Acne-like Rash Face Dry Skin Face Chest Arms

GT03 -
GT0401 -  ..
GT0402 - Side Effects Cetuximab Similar Symptoms Pulmonary Embolism
GT0403 - Energy Strength Rising Minimal Side Effects Cetuximab Treatment
GT0404 - Facial Skin Dryness New Side Effect Cetuximab Curel Lotion Prescribed
GT0405 - Curel Lotion Prescribed Facial Skin Dryness New Side Effect Cetuximab
GT0406 -
GT0407 - Follow up ref SDS D6 TQ6L, ref SDS D3 TQ6L.
GT0408 -
GT0409 - Yesterday, on 070418 Millie submitted the list of side effects,
GT0410 - ref SDS D9 PZ4W, shown in the record on 070329, ref SDS D4 QU8K, and
GT0411 - to facilite review this morning during the examination.  This morning,
GT0412 - after using the computer in the examination room to check side effects
GT0413 - of cetuximab, per above, ref SDS 0 D39M, there wasn't enough time for
GT0414 - the medical team to display the list on the computer screen for
GT0415 - comprehensive review.
GT0417 -  ..
GT0418 - On 070418 Millie also notified UCSF and Kaiser that she cannot
GT0419 - remember feeling better. ref SDS D9 PY6W  So far, previous low energy
GT0420 - has been significantly increased. as discussed with the medical team
GT0421 - on 070329. ref SDS D6 QG4G  This record indicates that loss of energy
GT0422 - listed as a side effect of cetuximab in the clinical trial Consent
GT0423 - documents received from UCSF on 070116, ref SDS A7 O64M, has been very
GT0424 - limited until recently.
GT0426 -  ..
GT0427 - There is a one hour rest after cetuximab treatments to help recover
GT0428 - from drowsiness associated with Benadryl pre-treatment, reported on
GT0429 - 060721, ref SDS 83 6L5F, and from fatigue caused by cetuximab.  This
GT0430 - hour provides opportunity to monitor for severe effects of treatment,
GT0431 - which have not occurred.  Vitals are taken to verify patients are
GT0432 - alert, reported later today. ref SDS E0 AW4L  Millie continues to
GT0433 - recover well enough treatments to drive home from San Francisco to
GT0434 - Concord, about 25 miles, a 40 minute drive in heavy traffic.
GT0436 -  ..
GT0437 - Within the past 3 weeks, beginning on 070329, Millie has been taking a
GT0438 - nap (sleeping) for several hours after getting home from treatments,
GT0439 - reported on 070412. ref SDS D8 D48I  This change from prior practice
GT0440 - may reflect accumulating fatigue from cetuximab.
GT0442 -  ..
GT0443 - Millie's vitals show evident decline in blood pressure since starting
GT0444 - treatment with cetuximab, particularly pulse, as shown in the record
GT0445 - today on treatment. ref SDS E0 AW4L  This change may reflect improved
GT0446 - fitness, which has been a goal Millie works hard to achieve, as a
GT0447 - component of quality of life, and to resist cancer, noted by the
GT0448 - primary care physician during the meeting at Kaiser on 070105.
GT0449 - ref SDS A5 MA9K
GT0451 -  ..
GT0452 - Low blood pressure is also a side effect of cetuximab, shown on the
GT0453 - Internet...
GT0455 -         ..
GT0456 -        FDA
GT0457 -        Patient Information Sheet
GT0458 -        Cetuximab (marketed as Erbitux)
GT0459 -
GT0460 -              http://www.fda.gov/cder/drug/InfoSheets/patient/cetuximabPIS.htm
GT0462 -  ..
GT0463 - The doctor commented on very minimal acne-like rash, and was pleased
GT0464 - Millie looks well while continuing weekly treatments for stage IV
GT0465 - cancer, showing little signs of cetuximab side effects.  On 070330
GT0466 - primary care physician commented similarly during examination at
GT0467 - Kaiser on how well and fit Millie looks, ref SDS D6 N49K, which aligns
GT0468 - with the report the day before at UCSF that Millie has avoided
GT0469 - significant acne-like facial rash. ref SDS D3 N49K
GT0471 -  ..
GT0472 - Skin blemishes, redness, inflammation and infection are also listed as
GT0473 - side effects of cetuximab, see again FDA, per above. ref SDS 0 WR4O
GT0474 - This issue was carefully reviewed during examination this morning in
GT0475 - connection with...
GT0476 -
GT0477 -        1.  Left arm (upper) erratic change intensity of rash currently
GT0478 -            diagnosed with IBC, and possibly compounded by Cellulitis,
GT0479 -            and/or side effects of cetuximab, per above. ref SDS 0
GT0480 -            F57K, and cat bite. ref SDS 0 P67J
GT0482 -             ..
GT0483 -        2.  Chest Right below collar bone rash reported Nurses Notes on
GT0484 -            070315, and observed at Kaiser on 070330, also possible
GT0485 -            side effect of cetuximab, cat bite, IBC, per above.
GT0486 -            ref SDS 0 583G
GT0488 -             ..
GT0489 -        3.  Chest Right above port catheter erratic skin blemish,
GT0490 -            possible infection, inflammation side effect of cetuximab,
GT0491 -            noted by Doctor Rugo, per above. ref SDS 0 S640
GT0492 -
GT0493 -
GT0494 -
GT0495 -
GT0496 -
GT0497 -
GT05 -

SUBJECTS
Cetuximab Clinical Study UCSF Drug Trial Clinical Examination IBC Su

H203 -
H20401 -  ..
H20402 - Cetuximab UCSF Clinical Study Treatment Begins 070201
H20403 - UCSF Clinical Study Treatment Cetuximab Drug Trial Begins 070201
H20404 - Drug Trials UCSF Has Other Clinical Study Treatments May Help Millie
H20405 -
H20406 - Follow up ref SDS D6 ZJ9N, ref SDS D3 ZJ9N.
H20407 -
H20408 - Background on Kaiser referral to UCSF for treatment on clinical study
H20409 - is reported on 070105. ref SDS A5 P256  Purpose of referral is to
H20410 - improve patient care with new treatment. ref SDS A5 PK7L  Case study
H20411 - on Kaiser and UCSF collaborating to expedite treatment is listed on
H20412 - 070130, ref SDS B0 4T5N, and reviewed again today, per above.
H20413 - ref SDS D3 RM4G
H20415 -  ..
H20416 - Jackie will coordinate to schedule blood draw for seven (7) vials on
H20417 - 070426 required to start the next cycle on the cetuximab study.  This
H20418 - was successful on 070329 with blood drawn in the Infusion Clinic.
H20419 - ref SDS D4 Q659
H20421 -  ..
H20422 - Millie has been fortunate to respond well to treatment for IBC with
H20423 - cetuximab alone, and no carboplatin...
H20424 -
H20425 -        1.  Clinical examination shows IBC inflammation subsiding.
H20426 -            ref SDS 0 M68J,
H20427 -
H20428 -        2.  CA 15-3 testing shows evidence of cancer falling.
H20429 -            ref SDS 0 087J
H20431 -             ..
H20432 -        3.  CT test 070326 finds no evidence of metastatic disease,
H20433 -            reviewed on 070329. ref SDS D3 LV57
H20435 -  ..
H20436 - Jackie advised that new patients accepted for the clincial study are
H20437 - no longer being treated with cetuximab alone.  Study data revealed not
H20438 - enough patients get favorable results with only cetuximab.  Therefore,
H20439 - new patients accepted for treatment in the clincial study are treated
H20440 - with both cetuximab and carboplatin.
H20441 -
H20442 -     [On 070607 Millie must sign a waiver to continue treatment with
H20443 -     cetuximab alone, as a result of the change in the clinical study
H20444 -     protocol. ref SDS E3 AT8L
H20446 -  ..
H20447 - Millie had fortunate timing coming along before this change to the
H20448 - study protocol, with the result that the doctor's planning options are
H20449 - significantly expanded, per below. ref SDS 0 K36G
H20451 -  ..
H20452 - On 070202 the primary care physician at Kaiser explained advantage for
H20453 - Millie getting treatment with cetuximab alone for as long as there is
H20454 - favorable response, ref SDS B3 QO6O, also, discussed at UCSF on
H20455 - 070130, ref SDS B0 PF3O, and again on 070201. ref SDS B2 XR3M
H20457 -  ..
H20458 - On 070301 Doctor Rugo noted that adding carboplatin to Millie's
H20459 - treatment would risk ability to maintain effective dose levels,
H20460 - because Millie had low blood counts without carboplatin.  Since adding
H20461 - carboplatin increases pressure lowering blood counts below a level
H20462 - save for treatment, ref SDS B8 VF6O, Millie might not be able to get
H20463 - treatments on the study, which has proven beneficial with cetuximab
H20464 - alone, as reported today. ref SDS 0 ST4J
H20465 -
H20466 -
H20467 -
H20468 -
H205 -

SUBJECTS
Schedule Treatment Cetuximab 070419 Weekly Through 070524 Clinical S

HA03 -
HA0401 -  ..
HA0402 - Schedule Treatment Start Cetuximab Carboplatin 070201
HA0403 -
HA0404 - Follow up ref SDS D6 N96O, ref SDS D3 N96O.
HA0405 -
HA0406 - Scheduling has proven a continuing challenge, listed above.
HA0407 - ref SDS D3 S63K
HA0409 -  ..
HA0410 - On 070315 Nola in the Infusion Clinic scheduled Millie for weekly
HA0411 - treatments through May 24th. ref SDS C6 159O  This continues to align
HA0412 - with examination today showing current protocol has been effective,
HA0413 - per above. ref SDS 0 M68J and further fits the strategy. ref SDS 0
HA0414 - K36G
HA0416 -  ..
HA0417 - Meetings and treatments continue on Thursdays, so the next meeting at
HA0418 - UCSF will be on 070426 to start the next cycle of treatment.
HA0419 -
HA0420 -
HA0421 -
HA0422 -
HA0423 -
HA05 -

SUBJECTS
Pulmonary Embolism Blood Clots Lung Disorder Enlarged Right Ventricl

HN03 -
HN0401 -  ..
HN0402 - Tired Breathing Difficulty Routine Activity Signals Pulmonary Emboli
HN0403 - Coumadin Treatment Pulmonary Emboli Family History Genetic Cause
HN0404 - Pulmonary Emboli Hypercoagulable Work Up PET Scan Test Compare History
HN0405 -
HN0406 - Follow up ref SDS D6 CV5L, ref SDS D3 CV5L.
HN0407 -
HN0408 - Background on pulmonary embolism and correlation with IBC treatment at
HN0409 - UCSF is reported in the record meeting at UCSF on 070130. ref SDS B0
HN0410 - CV5L  This was updated on 070329 when the CT test on 070326 failed to
HN0411 - report findings on pulmonary embolism, ref SDS D3 LZ6H, noted as well
HN0412 - the next day at Kaiser on 070330. ref SDS D6 NU55
HN0414 -  ..
HN0415 - Since cetuximab can cause blood clots, reported on 070116 reviewing
HN0416 - clinical study Consent documents, ref SDS A7 I75I, and since Millie's
HN0417 - patient history shows recurrent pulmonary embolism, reported on
HN0418 - 061012, ref SDS 91 294Q, and since family history of mother and son
HN0419 - shows blood clot problems, reviewed at Kaiser on 060722, ref SDS 84
HN0420 - 3D9T, Doctor Rugo planned to assess Millie's risk of cetuximab causing
HN0421 - interstitial lung disease, per above, ref SDS 0 G25K, and compounding
HN0422 - pulmonary embolism by investigating for progression of blood clotting
HN0423 - disease in the lungs with thin slice spiral CT testing. ref SDS B0
HN0424 - R16N  Evaluating progression of disease requires comparing current
HN0425 - conditions with findings in the test on 060930 that diagnosed
HN0426 - recurrent pulmonary embolism, and, also, enlarged right ventricle, as
HN0427 - discussed at Kaiser on 070202. ref SDS B3 T85F  This comparison was
HN0428 - performed by Kaiser in a test on 041217 that reported pulmonary
HN0429 - embolism found with an earlier test on 041103 was no longer
HN0430 - visualized, reported on 041230. ref SDS 51 PW3K
HN0432 -  ..
HN0433 - On 070330 the primary care physician reported that Kaiser has not
HN0434 - performed the required test. ref SDS D6 NU66  At this time, status of
HN0435 - pulmonary embolism remains unknown, and needs to be investigated for
HN0436 - risk analysis.
HN0438 -  ..
HN0439 - Millie's energy has improved, indicating reduced risk.  She continues
HN0440 - increased exercise at the gym, and vigorous hiking.
HN0442 -  ..
HN0443 - Affirmative test evidence with a thin slice spiral CT scan supports
HN0444 - assumptions from absence of clinical symptoms, e.g., hear attack
HN0445 - caused by highly lethal conditions like pulmonary embolism, reported
HN0446 - on 060722. ref SDS 84 BI5J  Activities like tennis that spikes the
HN0447 - heart rate reported on 070218, ref SDS B5 N06R, must performed with a
HN0448 - level of care that reduces benefits.
HN0449 -
HN0451 -  ..
HN0452 - INR 2.4 Blood Test Patient Stable for Coumadin Treatments Pulmonary Emboli
HN0453 -
HN0454 - Follow up ref SDS D6 FE9I, ref SDS D3 FE9I.
HN0455 -
HN0456 - On 070330 Millie's letter to Kaiser notified Gloria of INR stable
HN0457 - blood tests for past 2 months; continuing current Coumadin regimen.
HN0458 - ref SDS D5 ZH4H
HN0460 -  ..
HN0461 - INR will be tested next week.
HN0462 -
HN0463 -
HN0464 -
HN05 -

SUBJECTS
Examination Stethoscope No Findings Enlarged Right Ventricle Heart S

HV03 -
HV0401 -  ..
HV0402 - Examination Breathing Stethoscope No Finding Enlarged Right Ventricle
HV0403 -
HV0404 - Follow up ref SDS D6 Q35O, ref SDS D3 Q35O.
HV0405 -
HV0406 - Examination with a stethoscope today included multiple locations on
HV0407 - Millie's back and chest.  There were no findings of cardio pulmonary
HV0408 - issues from clinical examination.
HV0410 -  ..
HV0411 - After meeting with Doctor Rugo in the Oncology Clinic, Millie was
HV0412 - treated in the Infusion Clinic.  Vitals were taken twice.  The first
HV0413 - test at 0930 reported Sa02 100%. ref SDS E0 AW4L
HV0414 -
HV0415 -
HV0416 -
HV0417 -
HV05 -

SUBJECTS
Enlarged Right Ventricle Heart Disorder Cor Pulmonale Related Pulmon

I503 -
I50401 -  ..
I50402 - Cor Pulmonale Heart Disorder Enlarged Right Ventricle
I50403 - Heart Examination Not Ordered Investigate Enlarged Right Ventricle
I50404 - Enlarged Right Ventricle CT Test Aligns Patient Symptoms How Serious
I50405 -
I50406 - Follow up ref SDS D6 VJ4J, ref SDS D3 VJ4J.
I50407 -
I50408 - Background on heart disorder Cor Pulmonale from enlarged right
I50409 - ventricle, and plans for CT testing is reported on 070130. ref SDS B0
I50410 - VJ4J  Kaiser failed to perform the spiral CT test ordered by the
I50411 - primary care physician to evaluate enlarged right ventricle, reported
I50412 - above. ref SDS 0 CV5L
I50414 -  ..
I50415 - This issue is closely related to pulmonary embolism, reported by the
I50416 - primary care physician on 061228. ref SDS A1 JU7L  Continued subsiding
I50417 - of symptoms for pulmonary embolism reported on 070301, ref SDS B8
I50418 - SX6N, and again today signal Cor Pulmonale, also, seems under control,
I50419 - however, the actual status is unknown, per above. ref SDS 0 E44L
I50421 -  ..
I50422 - During the meeting at Kaiser on 070330, the primary care physician did
I50423 - not make referral for examination by a heart specialist, nor on
I50424 - getting a treadmill test, ref SDS D6 SY5N, discussed by Doctor Rugo
I50425 - during the meeting at UCSF on 070130. ref SDS B0 RV3O
I50427 -  ..
I50428 - Since cetuximab has a documented history of causing heart attacks, use
I50429 - of this drug requires monitoring patients with heart disorders.
I50430 - Millie's history of enlarged right ventricle reported in the CT test
I50431 - on 060930, shown by review on 061012, ref SDS 91 7E5L, should be
I50432 - investigated to evaluate compounding effects of cetuximab treatments.
I50433 -
I50434 -
I50435 -
I50436 -
I50437 -
I50438 -
I50439 -
I505 -